Sorrento Therapeutics
BiotechUSAClosed 2023
Total Raised
Undisclosed
Peak Valuation
Undisclosed
Employees
—
Year Collapsed
2023
Business model
Clinical- and commercial-stage biopharmaceutical developing therapies for cancer, pain, and autoimmune disease.
In brief
A biopharmaceutical company with a broad portfolio spanning cancer, pain, and COVID-19 therapies, notable for having turned down a billion-dollar buyout offer in 2020 during the height of COVID-related biotech optimism. Persistent cash burn across its wide pipeline, a legal dispu…
See the What Happened tab for the full account.
Key facts
- Founded
- 2009
- Closed
- 2023
- Headquarters
- San Diego, USA
- Industry
- Biotech
- Employees
- —
- Revenue
- Undisclosed
- Founders
- Henry Ji
Related failures
Vedere Bio
2019–2023Biotech · USA
Ran out of funding$77M9 Meters Biopharma
2016–2023Biotech · USA
Ran out of fundingUndisclosedAcorda Therapeutics
1995–2024Biotech · USA
Ran out of fundingUndisclosedAthersys
1995–2024Biotech · USA
Ran out of fundingUndisclosedEiger BioPharmaceuticals
2008–2024Biotech · USA
Ran out of fundingUndisclosedHumanigen
1999–2024Biotech · USA
Ran out of fundingUndisclosed
Often compared with: Regeneron, Vertex Pharmaceuticals.